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Cancer Services Report
regional

Our central nervous system

education, both to patients and providers. We

and spinal cord. The brain

trust that the provider reading this report will

is the center of thought,

find something that assists them either in

memory, emotion and speech,

caring for their patients or providing a referral.

nerves carry messages between the
J. Laffey, MBA

Cancer Services Regional Director

An important part of our cancer program is

is comprised of the brain

while the spinal cord and cranial

William

director

brain and the rest of the body. Is it

We also trust that our annual report gives the
patient or family member who reads it something
equally important

—

a reason for believing that

any wonder that the thought of a

a team of experts at Aurora is dedicating their

tumor in any part of the central nervous system elicits

professional lives to the prevention, diagnosis

more emotion among patients and physicians than any

and treatment of cancer, whether it be located

other cancer site? Although relatively few in number

in the central nervous system or anywhere else.

(about 1 .3% of all cancers), tumors in the central nervous
system are rarely non-cancerous.

Aurora Health Care has recognized both the emotional
power and the relatively low 5-year survival rates of
these cancers and has organized a collaborative team
of experts and provided them with advanced technology
to address the complexity of these cancers. From
medical and surgical interventions to the non-invasive
Gamma Knife and comforting psychotherapy, the
techniques and treatments contained within this report
discuss the breadth of the topic.
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St. Luke’s Medical Center
chairman’s

It is hard to believe another

Several new exciting developments have taken

year has come and gone.

place at St. Luke’s Medical Center this year.

It has been an exciting year.

St. Luke’s was chosen as one of 50 facilities

On September 25, 2001

in the nation to be licensed by the Nuclear

the Second Annual Men’s

Regulatory Commission to utilize vascular

I

Health Conference took place

Jeffrey A. Derus, MD

report

brachytherapy to treat coronary arterial disease.

at the four Points Sheraton in

The first case was done in March 2001. We

South Milwaukee. Harry Belafonte,

have now done over 90 cases and are quite

Cancer Committee Chairman

a prostate cancer survivor, was the

excited about its ability to reduce coronary

keynote speaker. Also, Mark Samuelson of the Center

artery re-stenosis. Also, intensity modulated

for Disease Control spoke about being proactive in

radiation therapy (IMRT) will be available at

one’s health. Both speakers were excellent and were

the end of 2001. This is effective in treating

well received by the 800 people who attended the event.

previously radiated cancers and the treatment

Other health care issues were also addressed including

of tumors in the proximity of delicate organs

hypertension, glaucoma, diabetes mellitus, coronary

such as the eyes and spinal cord. The IMRT is

artery disease, stroke prevention and colon cancer. I

utilized to treat primary metastatic brain tumors,

would like to thank the many physicians who were on

pancreatic tumors, liver tumors, prostate cancer,

hand to answer questions. This year the Buddies Against

head and neck tumors and lung cancer.

Prostate Cancer, Bob Reitman, Gary Gruneau and Ken
Sanders, sponsored their annual golf outing. The monies

St. Luke’s is now providing positive emission

raised by the event helps support the Men’s Health

tomography (PET scanning). This technology

Conference and prostate cancer awareness. I would like

is useful in diagnosis and staging certain types

to thank them and everyone who helped make this year’s

of oncologic cancers. It is specifically used to

event a tremendous success.

help distinguish solitary pulmonary nodules,
small cell carcinoma of the lung, recurrent
colorectal cancer, lymphorna, melanoma,
brain tumors, head and neck carcinoma and
breast cancer.
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The Gamma Knife continues to be an excellent tool for

Finally, I would like to personally thank the

treating delicate brain tumors. It precludes the need for

members of the cancer committee for their

open brain surgery and/or hospitalization. These patients

hard work and dedication throughout the year.

are treated as outpatients and continue to do well.

I would specifically like to thank Patty Abella,
Bill Laffey, Lisa Robinson, Marija Weidman

The community outreach activities that have taken

and Phil Whitton. They have made the Cancer

place throughout the year can be found in the Community

Committee as well as cancer services throughout

Outreach Activities portion of the annual report. Again,

the state and the metro area a great success.

the Vince Lombardi Golf Outing and Vince Lombardi
Award Dinner Ball were a great success. I would like
to thank all the volunteers for their continued support
and generosity for the Vince Lombardi Cancer Clinic
and programs. The breast cancer “Race for the Cure”
took place on October 21, 2001. The monies raised
from the event go to breast cancer research and grants
throughout the Mihvaukee area. On September 7
and 14, 2001 the Girl Scouts had an event that over
1,500 girls attended to earn a patch developed to
1
.t’&S.’:t.
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increase breast cancer awareness.
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Aurora Sinai Medical Center
chairman’s

The Cancer Program at Sinai

We were pleased to see thought given to a

Samaritan Medical Center,

geriatric oncology program at our institution

now Aurora Sinai Medical

and noted continued activity of the Lung Cancer

Center (ASMC) as of

Task Force. Lung cancer is second only to breast

October 15, 2001, continues

William L. Donegan, MD, FACS

report

cancer in frequency at ASMC and is still the

to concentrate on programs of

most frequent cause of cancer deaths nationally

service, education and research.

among men and women. Paradoxically, it is the

The Committee added several

most preventable cancer, but the obstructions

Cancer Committee Chairman

new members this year to expand

to progress are many. The Breast Health Center

its multidisciplinary focus into all phases of

expanded its services, adding prosthesis supply

oncologic activity.

and fitting. The safety of our patients remains a
top priority. Our pharmacy made cancer therapy

The oncology program at ASMC has new visibility

even safer at ASMC with innovative policies

on a national level through participation in the ACOS

related to prescription writing and to ordering

Commission on Cancer’s (CoC) National Cancer Data

and administration of systemic cancer therapy.

Base. With our consent, the CoC supplies data about
our cancer program to the American Cancer Society’s

Research continues on several fronts.

National Information Center (NIC). The NIC makes this

Recruitment for the National STAR Breast

information available to the public. Information includes

Cancer Prevention Trial has passed the halfway

the services available at ASMC, the number of cancers

mark. Participation locally, which is coordinated

treated each year and their stages. The NIC is available by

at ASMC, now totals 76 women. We are also

phone (1 -800-ACS-2345) or the Internet (www.cancer.org).

on the forefront of research in axillary sentinel
node biopsy (SLNB) which is an important
advancement in the treatment of women with
breast cancer. SLNB makes axillary dissection
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unnecessary for the majority of patients, reducing the

treatment at ASMC stimulated plans for a

potential morbidity of treatment. Participation in ECOG

regular working breast conference as a source

protocols of adjuvant and palliative therapy continues to

of consultation, treatment planning and

offer the latest forms of treatment to patients with many

information exchange.

forms of cancer. For men, a prostate cancer screening
program (SELECT) is in place under the direction of

Progress and opportunities continue to rise

Gary Shapiro, MD. Prostate cancer is the most frequent

before us. We look forward to closer connections

incident cancer among men and can be detected at an

with other Aurora centers through video

early stage with digital examination and testing for

conferencing, and to what is expected eventually

prostate specific antigen. Harry Belafonte spoke this year

to be a closely coordinated metro oncology

at Aurora’s Second Annual Men’s Health Conference to

program with an integrated data system.

promote prostate cancer screening. This famous entertainer
is an international figure in the effort against prostate

This year’s Metro annual report focuses on brain

cancer through screening and appropriate treatment.

cancer, an infrequent but devastating form of the
disease. Fortunately, new technology is providing

I wish to applaud those responsible for the continuing

improved treatment. Again this year, I would like

success of our weekly tumor conference. This conference

to thank the members of the Cancer Committee

is a popular forum for clinical oncologists in multiple

for their dedication and hard work and welcome

disciplines, and has an important educational function.

the new Cancer Committee members who are

We welcomed the new digital projection equipment for

so important to the continuing vitality of our

slides and x-rays that was made available by funds from

cancer program.

the ASMC Continuing Medical Education Committee.
Now x-rays can truly be seen from the back of the room.
The large number of cases of breast cancer seeking

cancer
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West Allis Memorial Hospital
chairman’s

Over the past year, many

the education component of cancer services with

at West Allis Memorial

weekly cancer conferences, Grand Rounds and

Hospital. The most

annual seminars. Members continue to actively

appreciable change has

participate in the American College of Surgeons

the Aurora Women’s Pavilion.
Consistent with our commitment

Cancer Committee Chairman

to providing the most comprehensive
services to our community,

offers

the Aurora Women’s Pavilion

global care to women focusing on all of the stages

of their lives. Not only will it provide complete medical
services

Cancer Committee members remain active in

changes have taken place

been the construction of

Rakesh jagetia, MD

report

such as primary care, obstetrics and gynecology,

Oncology Group National trials, RTOG protocols
and other such national cooperative group studies.
The members have been committed to the
community through lectures, participation in
community events and by volunteering their
time at Aurora’s Second Annual Men’s Health
conference. Coupled with the integration of the
cancer services throughout the Metro Region,

cancer care and programs pertinent to midlife transition,

we have been able to provide the latest in cancer

but also it will provide programs in education, lifestyle,

care to our patients.

fitness and complementary medicine.
It has been an honor and a privilege to chair
With the new addition, the Radiation Oncology suite will

the Cancer Committee at West Allis Memorial

shift to the Aurora Women’s Pavilion. State-of-the-art

Hospital. I would like to thank each and every

equipment will allow us to continue to take advantage of

member who has contributed to the program.

technological advances so that patients will have access to

Because of these efforts, the cancer program

the latest treatments in cancer care, such as 3-D conformal

has rernaine very successful in providing the

external beam radiation therapy and IMRT

highest quality of care.

modulated radiation therapy.
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Aurora Medical Center in Hartford
chairman’s

While Hartford Memorial

Our integration of cancer committee meetings

Hospital’s name has

with tumor boards has allowed for better

changed to Aurora

professional discussion of interesting or

Medical Center in

challenging cases. Collaboration with physicians

Hartford, our commitment
to cancer care excellence
has not changed. The Cancer
Jonathan Treisman, MD

report

Committee has grown over the

at St. Joseph’s Hospital in West Bend has
increased the educational value of these
conferences. Our physicians also have increased
participation in national cooperative group

Cancer Committee Chairman

past year since its inception. We
are fortunate to have as members individuals dedicated

studies to improve access to the latest diagnostic
and treatment options for their oncology patients.

to the enhancement of the quality of patient care in
Washington County.

As always, our community continues to support
local events such as Relay for Life, lectures

Due to both the enthusiasm of these professionals,

and other programs which address the important

as well as our connection with the resources of Aurora

areas of education, prevention, and early

Health Care, county residents now have local access to

diagnosis. Our ability to provide support

services such as the Cancer Counseling Center, the only

groups to patients and families is further

one of its kind in Wisconsin, and one of very few in the

evidence of the professionalism and dedication

country. Area physicians are able to make referrals for

of our providers and volunteers.

patients whose treatment calls for brachytherapy or who
may require PET scanning for treatment planning. The

Once again, let me express collective appreciation

breast health program at the Aurora Medical Center is

from all who participate in the Aurora Medical

coordinated by a nursing professional specializing in

Center’s Cancer Committee and Tumor Boards

this field.

to those who not only make our jobs easier, but
who impact our patients’ health status in so many
positive ways.
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Aurora Health Care 2001
regional

cancer

Tracking cancer incidence,

report

For the year 2000, the Clinical Data Registrars

treatment and outcome is

accessioned over 3,138 new cancer cases

one of the most important

within the Metro Region of Aurora Health Care.

fights in the war against

St. Luke’s Medical Center, the largest hospital

cancer. It is through quality

in the region, saw 2,070 cases, of which 1,830

data that caregivers and researchers
strive to increase survival trends
Lisa Robinson, RHIA, CTR

registry

by utilizing the most efficient treatment

were analytical. West Allis Memorial Hospital’s
cases grew to 608, of which 559 were analytical.
Aurora Sinai Medical Center accessioned 348

Clinical Information Services

methods to improve and eventually

cases, of which 319 were analytical. Aurora

eliminate the morbidity and mortality caused by cancer.

Medical Center in Hartford saw 112 new

According to the annual report of the National Cancer

cancer cases, of which 79 were analytical.

Institute, the rate of new cancer cases and deaths from
all cancer cases combined has declined over the last

In addition to collecting and following cancer

10 years, despite the increasing size of the American

cases for the approved cancer registries of the

population. From this we can draw the conclusion

hospitals in the Metro Region, the registrars were

that information is the backbone of new knowledge

instrumental in bringing the larger ambulatory

and technologies.

clinics (Wilkinson Medical Centers and
Washington County Aurora Health Centers)

Aurora Health Care’s Metro Region encourages hospitals

current in cancer reporting to the State of

and clinics to collect and report cancer data to the

Wisconsin. Additional activities in which the

National Cancer Data Base and the Wisconsin Cancer

registrars were involved included coordinating

Reporting System which in turn reports information to the

the majority of the tumor board and breast cancer

North American Association of Central Cancer Registries,

conferences at each of the hospitals, participating

the Centers for Disease Control, including the National

in the ad hoc data collection of the ACOS patient

Center for Health Statistics.

care evaluation studies of the brain and the liver,
assuring physician review of 10% of the

pagejO
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analytical abstracted cases, and submitting reports and

fourteen states participate in the CBTRUS;

data for over 31 requests to hospital administrators,

Wisconsin does not. The CBTRUS is a not-for-

marketing managers and physicians.

profit corporation committed to providing a
resource for gathering and disseminating data on

To stay abreast of the ever changing rules and regulations

all primary brain tumors, benign and malignant.

in the registry setting, the registrars participated in a

Before the CBTRUS was established, reporting

number of continuing education events including the 27th

in the U.S. was limited to only malignant brain

Annual National Cancer Registrar’s Association (NCRA)

tumors. However, research has proven that

meeting, the NCRA hosted a satellite teleconference on

benign tumors often impose the same costs to

the new International Classification of Diseases for

society in terms of medical care, care fatality

Oncology Coding 3rd Edition, and the 33rd Annual

and lost productivity. Also, it has become clear

Southeastern Wisconsin Cancer Conference. In addition,

that certain benign brain tumors may become

Aurora registrars hosted and coordinated the Wisconsin

malignant over time. Thanks go out to Sheri

Cancer Registrars Association’s (WCRA) 2001 Spring

Hackbarth, RHIA for benchrnarking the brain

Conference at Aurora Sinai Medical Center and arranged

statistics, and to the following registrars for

the fall WCRA Annual meeting. Congratulations go out

their dedication in providing accurate and timely

to our registrar Mary Kissinger, RHIA, CTR who serves

oncology data collection and follow-up.

as President and immediate past president of WCRA.

Cancer Registrars
Within this year’s annual report is an in-depth collaboration

Sharon Collison, RHIT, CTR

of brain/CNS tumor data, incorporating data from the

Deborah Dries, RHIT, CTR

National Cancer Database’s 2000 Patient Care Evaluation
study, in which both benign and malignant brain tumors
were reviewed. The data displayed as Aurora Health Care

Judith Ferkans, RHIT
Cynthia Ganzel, RN, RHIT, CTR
Sheri Hackbarth, RHIA
Jamie Keen

Metro Region (AHC-Metro) is information combined

Mary Kissinger, RHIA, CTR

from St. Luke’s Medical Center, Aurora Sinai Medical

Tracy Miller

Center and West Allis Memorial Hospital. This compilation

Patricia Norris, RHIT

of data is compared to the Central Brain Tumor Registry

Karen Pollock

of the United States (CBTRUS). The CBTRUS, was

Marilyn Raciti, RHIA, CPHQ

established in 1992 and provides the largest aggregation
of population-based data on all primary brain!CNS

.

Jacqueline Schramm, RHIT
Jane Seymour, RHIT, CTR

tumors in the United States. Currently,

cancer
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Brain Tumors:
introduction

and

epidemiology

A
Perhaps, there is no more
distressing diagnosis for

in the CNS and its coverings. After a peak

patients and physicians alike

incidence in childhood, they decrease between

than that of a brain tumor.

the ages of 15 and 25, only to increase

Unlike tumors in other

exponentially from age 25 to 70. Brain tumors

locations, the clinical course
of central nervous system
P. Daniel Suberviola, MD, FRCSC, EACS

About 9% of all primary neoplasms originate

(CNS) tumors is not only

Chairman, Neurological Surgery

dependent on tissue histology

are twice as common in men as in women,
and the second most common malignancy
in childhood. Twenty percent are secondary
malignancies. Just as they differ by sex and age,

but also on their anatomic location. A histologically

CNS tumors vary by country, ethnic group, and

benign tumor located in a critical area can have as

also over time. Mortality rates from brain tumors

much of a devastating effect as a pathologically highly

in the United States are about 6/100,000/year.

malignant neoplasm.

When one takes a global perspective, this number
is as high as 10/100,000/year in Scandinavia

The epidemiological study of brain tumors is frequently

and as low as 4/100,000/year in Japan. Because

limited by the lack of histologic confirmation of the

all these countries have similar, highly developed

diagnosis. Without adequate pathology review, tumors

medical systems, race may be responsible for

are likely to be misclassified. Tumor location may

the difference. There appears to have been an

preclude obtaining tissue diagnosis, making it impossible

increased incidence in these tumors over the

to determine if the tumor is primary or metastatic, benign

last 100 years. This may be due to the development

or malignant. Small tissue samples obtained through a

of better diagnostic imaging techniques,

stereotactic biopsy or limited resections introduce sampling

improved standard of living with a greater

errors. Even when sufficient tissue is available, a conclusive

access to specialized medical care, and a longer

diagnosis sometimes cannot be established. Epidemiologic

living population.

study has also been influenced by the histologic variety
of CNS tumors and the varying nomenclatures and

Although genetic and environmental influences,

classifications that have been used in different parts

including radiation, chemical carcinogens and

of the world and at different times.

viruses, have been implicated as causative agents,

in

depth

articles
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their etiology remains largely unknown. Retinoblastoma

neoplasms in laboratory animals. Interestingly,

and chemodectorna are examples of tumors with a clearly

an increased risk has also been suggested for

established familial incidence. Brain tumors are also

mathematicians and clergymen.

frequent in association with other hereditary disorders,
such as neurofibromatosis. The association between

RNA and DNA viruses have been implicated

primary brain tumors and primary tumors in other sites,

in the development of brain tumors and of

such as meningiomas and breast cancer or retinoblastomas

recent, evidence is accumulating that they may

and osteosarcomas, also suggests a genetic link.

be a factor in CNS carcinogenesis. A variety of
tumors have been induced in laboratory animals

There is increasing evidence that exposure to diagnostic

using the Rous Sarcoma Virus, SV 40, JC

or therapeutic ionizing radiation may increase tumor risk,

papovavirus and others. C-type viruses and

although atomic bomb survivor data show that the risk is

DNA from the BK virus, a human papovavirus,

only marginal. Several studies have revealed an increased

have been detected in human CNS neoplasms.

brain tumor incidence in children who were treated with

Also, a single case of a high-grade astrocytoma

low dose radiation for tinea capitis. Radiation-induced

in a patient with progressive multifocal

atypical meningiornas are a well-known late complication

leukoencephalopathy due to infection with

of external beam radiation treatment. Dental x-ray’s

the JC virus has been reported.

also have been associated with an increased risk of
meningiornas, especially in women. The role of

Other factors, such as alcohol consumption,

non-ionizing radiation as an etiologic factor for brain

tobacco abuse, the use of drugs (particularly

tumors remains controversial. Studies on the effects

anticonvulsants) and even noise have been linked

of electromagnetic fields from power lines, computer

with a heightened risk for CNS tumors, but the

monitors and the like, remain inconclusive.

findings are difficult to interpret and a direct
association does not exist. Although much

page
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Exposure to benzene and other organic solvents, aromatic

is known, the epidemiology of brain tumors

hydrocarbons, vinyl chloride, phenol, lubricating oils

remains poorly understood. The combined results

and other chemicals, has been associated with a greater

of studies carried out during the last 20 years,

risk for developing a CNS tumor. A higher incidence of

and others in progress, as well as the introduction

brain tumors has been shown in occupations that involve

in epidemiologic studies of molecular biology

contact with chemicals encountered in oil refining,

and molecular pathology will do much to identify

pharmaceutical and chemical industries, airplane and

the chemical and biologic agents responsible

electronics manufacturing, and farming. Some of these

for the development of CNS tumors and open

chemicals have also been successfully used to induce

a door for their prevention and cure.

in

depth

articles
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•

CBTRUS

•

AHC-Metro

Pet the Central Brain Tumor Registry of the United States
(CBTRUS) the incidence of all primary (benign and malignant)
brain and CNS tumors is higher in males than in females,
based on the 2000 US Standard Population Rate. In comparing
the distribution by sex among Aurora Health Care’s Metro
Region and the CBTRUS, the occurrence rate in males is exactly
the same as seen at the national level with 52% being male
and 48% being female.

•

Per the CBTRUS the mean age of diagnosis for
all primary brain tumors is 54. The incidence
of Glioblastoma Multiforme (GBM) and

CBTRUS

• AHC-Metro
1-9%—

I

I

meningiomas increases with age. The incidence
for all brain tumors is highest among the 75-84
year olds. However, the different histologies
have different age distributions.
Here at AHC-Metro 81% of our brain/CNS tumor
incidence occurred from age 45 and older with
the highest concentration in the 55-74 age range.
In general Aurora’s Metro Region saw younger
patients than were reported through the CBTRUS.

cp.

Ependyjoma

Tmors of the Cr4sial and Spinal erves

When comparing the World Health Organization (WHO)
Histology Groupings of brain and central nervous system
tumors reported by the CBTRUS to Aurora Health Care’s
Metro Region (AHC-Metro), you will find AHC-Metro saw a
larger percentage of tumors of the meninges (33% vs. 27%),
cranial/spinal nerves (22% vs. 7%) and lymphomas (4% vs.
3%) and saw a fewer number of those tumors of the
neuroepithelial tissue (30% vs. 47%) than those reported
for the CBTRUS. This disparity may be attributed to AHC
being the first facility in the State of Wisconsin to offer the
Gamma Knife procedure to patients who suffer from tumors
of the meninges and tumors of the nerve sheath.

in

depth

articles
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Radiology Imaging
of

brain

The imaging of brain tumors

tumors

more pronounced enhancement (Figure YA & YB).

continues to improve, with

Brain metastases typically densely enhance

newer techniques and

after contrast administration (figure 2) and are

more sensitive equipment

multiple. Unfortunately, MRI is not specific in

having been developed over

predicting the histology of brain tumors and

the past several decades.

cannot reliably estimate the grade of tumors.

Common diagnostic tools include
Mark Glazer, MD, Neuroradiologist

CT (computed tomography),

More recently, MR spectroscopy has been

Department of Radiology

MRI (magnetic resonance imaging),

utilized in the evaluation of brain tumors.

and more recently magnetic resonance spectroscopy

This technique involves the analysis of chemicals

(MRS) techniques. PET (positive emission tomography)

that are involved in body metabolism, and more

scanning has remained of somewhat limited use in

specifically, in how metabolic heterogeneity can

brain imaging.

be measured in brain tumors (1A). Brain tumors
usually have an abnormal spectral analysis with

The radiological evaluation of brain tumors usually

an increased choline and phosphomonester level

consists of CT and MRI. CT is usually the first study

and a decreased NAA (N-acetyl aspartate) level.

ordered and can reveal an unsuspected brain tumor in

An alkaline pH is also commonly seen in

a patient with headaches, for example. Depending on

association with high lactate levels. MRS patterns

the age, location, and appearance of the tumor, some

can be analyzed before, during, and after

information can be gained regarding possible etiology.

chemotherapy or radiation therapy to assess

However, most tumors ultimately deserve MRI evaluation

for interval changes/responses to treatment.

with intravenous contrast administration.

for example, increasing choline levels over time
is a worrisome sign for malignant degeneration.

MRI is the most sensitive test available to detect and

A decrease in choline levels suggests improvement.

characterize brain tumors. Less aggressive primary brain

Choline is also decreased in chronic radiation

tumors, or gliomas, usually are well defined on MRI, and

necrosis. There is no general agreement about

demonstrate little if any enhancement. More aggressive

the ability of MRS to accurately gauge high-

gliomas are usually of heterogeneous signal intensity on

grade vs. low-grade tumors.

MRI with irregular borders. These tumors demonstrate

page
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PET scanning has had a somewhat limited role to date in

necrosis after therapy, whereas FDG uptake

the workup of most brain tumors. In general, larger series

into an enhancing mass suggests viable tumor

have demonstrated that more aggressive brain metastases

remains. The limitation of FDG is in detecting

usually have higher uptake of FDG (2-{ 18F}-fluoro-2-

low and some intermediate grade tumors.

deoxy-d-glucose) than less aggressive tumors (2). A
poorer prognosis can be expected in patients with elevated

The future of radiology tumor imaging looks

FDG uptake in a brain tumor. This too can be studied

promising, especially with advances in functional

following therapy; absent FDG uptake would suggest

MRI and MR spectroscopy. Tumor specific
agents may offer additional promise, as well
as combined CT/PET imaging.

Figure JA MR spectroscopy (MRS) scan.

Figure 2 MRI after contrast showing multiple
brain metastasis.

Figure 1 B Aggressive tumor seen on MRI
with pronounced enhancement.
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Gamma Knife Radiosurgery
for

primary

brain

tumors
I

year, but our forecasts were off by half. In the two
years since the center opened, we have treated over
200 patients using Gamma Knife radiosurgery.

Although it is technically restricted to treating
brain lesions, the Gamma Knife can treat a
whole spectrum of indications
Kenneth Bastin, MD

Arvind Ahuja, MD
Midwest Neurosurgical Associates, SC

Department of Radiation Oncology

—

malignant and

benign tumors, metastatic cancer, arteriovenous
malformations and functional lesions such as

Not long ago, it was almost unimaginable: a surgical

intention tremors and trigeminal neuralgia,

treatment for brain tumors that did not involve a conventional

formerly known as tic douloureux. All patients

incision, thus eliminating bleeding and greatly reducing

treated with Gamma Knife have had independent

the risk of post-operative infection. A procedure performed

consultations with a neurosurgeon and radiation

under a local intravenous anesthesia, with discharge the

oncologist, and every case is prospectively

same day or the next day. But all that is commonplace

presented at St. Luke’s Medical Center’s Tuesday

today with Gamma Knife radiosurgery, which focuses up

morning Brain Tumor Conference.

to 201 cobalt-60 beams of gamma radiation at a central
point of “convergence” within the brain.

Gamma Knife radiosurgery is complex, requiring
the coordinated efforts of neurosurgeons, radiation

Gamma Knife radiosurgery has been known for some 50

oncologists, neuroradiologists and medical

years, but it has only come into widespread use with the

physicists. The strategy is to accurately identify

advent of modern imaging techniques, such as enhanced

a target with diagnostic imaging, generate

MRI and CI.

3-D images of the target and radiation-sensitive
brain structures, then create a treatment plan

In December 1999, St. Luke’s Medical Center became the

that divides the brain target into multiple

first medical center in Wisconsin to open a Gamma Knife

treatable regions, each of which will be a point

Center to treat patients with primary brain tumors. At the

of convergence. This allows the overall target to

time, we expected to treat approximately 50 patients a

receive a high dose of radiation while significantly
sparing adjacent, normal tissue.
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The procedure lasts between one and three hours. Under

for example, entail initial surgical intervention,

local anesthesia, a lightweight four-pinned frame is placed

conformal external radiation, chemotherapy and

on the patient’s head to hold him or her still. Using either

clinical trial options for anticipated eventual

a CT scan, an enhanced MRI or an angiography, an image

local failures. The role of Gamma Knife treatment

map is made of the patient’s brain, images of the brain are

for such tumors requires further definition via

transferred to a computerized treatment planning system,

clinical trials and outcomes studies.

which isolates the target area and determines its coordinates.
The patient’s head is then positioned inside a helmet that

Benign primary tumors should be surgically

has 201 portals through which the gamma rays are emitted.

removed by the neurosurgeon whenever they

Throughout, the patient is sedated and feels no pain.

cause local symptoms, mass effect or when a
biopsy is required. for a clinically diagnosed or

Overnight hospital observation depends on the patient’s

recurrent benign tumor, Gamma Knife treatment

specific characteristics, but given the typically low risk

offers a non-invasive but highly effective method

of acute morbidity, Milwaukee-area patients may be given

for tumor control. The historically published

the option of immediate discharge with planned follow-up.

control rate for acoustic neuromas, for example,
exceeds 85 percent, with minimal risk of

With malignant primary brain tumors, Gamma Knife

treatment complications.

treatment is inherently more complex than when it is
used for benign lesions because of the typical blurring

On balance, our overall experience treating

of malignant tumor margins. That is especially true in

benign and malignant brain tumors at St. Luke’s

edema-producing tumors, which can result in underestimating

Gamma Knife Center has been positive, for

and undertreating of the tumor. In these cases, Gamma

clinically diagnosed or recurrent benign brain

Knife radiosurgery may be offered following external

tumors, it offers a highly effective, viable

beam radiation that incorporates field margins around

alternative to surgery. And, with the continuing

the enhancing radiographically visualized target.

evolution of clinical innovations and advances
in radiographic imaging, we are optimistic that

Many patients have malignant brain tumors that exceed

Gamma Knife “boosting” will have a greater

the technical size limits of Gamma Knife treatment. for

role in combating newly diagnosed and recurrent

patients meeting treatment criteria, the radiographic response

malignant brain tumors in the future.

to, and local control from, Gamma Knife treatment is
encouraging; however, long-term survival nevertheless
remains suboptirnal. Current treatment strategies for a
high grade tumor such as glioblastoma multiforme,

in

depth

articles

pageJ9

r’

Neurosurgical Advances
in the treatment of

.,

brain

.;

tumors

I
I

Many benign tumors

—

acoustic neuromas,

meningiomas and pituitary adenomas

—

can be

effectively treated surgically. When symptoms
such as weakness, numbness or diminished
consciousness are rapidly progressing, an
immediate therapy is necessary. N eurosurgical
intervention can reduce the mass causing the
Cully R. White, DO

Arvind Ahuja, MD
Midwest Neurosurgical Associates, SC

deficit and restore some or all of the function.

Midwest Neurosurgical Associates, SC

Cancer of the brain or spinal cord is relatively rare,

Acoustic neuromas can be surgically resected.

representing only 1.5 percent of all cancers reported in the

This allows for definitive diagnosis, complete

United States. Nevertheless, its incidence has increased

tumor removal and possible preservation of

50 percent over the past decade. According to the

hearing. With an open surgery, however, there

American Brain Tumor Association, about 20,000 people

is risk of infection, hemorrhage or damage to

are diagnosed with primary brain tumors each year, and

the facial motor and/or sensory nerves. Gamma

approximately 50 percent experience relapses despite

Knife stereotactic radiosurgery is proving highly

aggressive treatment.

effective in treating acoustic neurornas with
decreased perioperative morbidity; however, there

Regardless of the type of brain tumor, the neurosurgeon’s

may be some delayed effect on facial motor or

challenge has always been to locate and isolate the lesion,

sensory function. Acoustic neuromas larger than

and determine whether it can safely be resected without

3 cm must be treated with conventional surgery.

sacrificing function.
Neurosurgery is often successful for total or
Surgical resection can successfully treat both benign

subtotal resection of meningiornas. Some

and malignant tumors. The type of tumor, size, location,

meningiomas have a large blood supply, however,

symptoms and the neurological deficit caused by the brain

and the tumor cannot be safely resected without

tumor help determine if surgical resection is a viable option.

substantial blood loss. To reduce this blood loss,
endovascular therapy is used to block off the
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feeding arteries. A catheter is inserted into the patient’s

build a 3-D model of a patient’s head, the

femoral artery, and advanced to the brain and the artery

neurosurgeon can navigate to the tumor through

supplying the tumor. Particles such as PVC or glue are

the safest and most direct path, with a smaller

injected to close off the tumor’s blood supply. Surgical

incision and a smaller opening in the skull. The

resection is performed a day or two later, but with

Stealth technology also lets us avoid important

significantly less blood loss, thereby decreasing the

brain structures before they can even be seen

need for blood transfusion. For meningiomas that are

in the surgical field.

deep or in delicate areas, radiosurgery with Gamma
Knife is au effective alternative.

Although we are able to approximate the location
of the eloquent brain that corresponds with

Most malignant brain tumors are metastatic. The two most

certain functions, we find that these areas do

common primary sites are lung and breast carcinomas.

vary among individuals. To identify these

When brain metastases are solitary, neurosurgical resection

eloquent areas, we often employ brain mapping.

is the treatment of choice. Stereotactic radiosurgery
with Gamma Knife is appropriate for multiple metastatic

Brain mapping is truly a team effort. The

lesions, especially melanomas and renal cell cancers.

neurosurgeon exposes the areas of the brain
thought to be affected, while the patient

—

who

The most common primary malignant brain tumors in

is awake and alert

adults are gliomas (astrocytoma, anaplastic astrocytoma

or other specialist trained in the technique. The

or glioblastoma multiforme), accounting for 65 percent

patient’s head is fixed in place to keep it immobile.

—

is examined by a neurologist

of all primary central nervous system tumors. Some
gliornas may be safely resected both initially and at the

If the area of the brain involved includes the

time of recurrence, depending on the stage and location.

speech center, the neurologist might show the

However, complete resection is often difficult, because

patient pictures of objects that are normally

gliomas (fibrillary, anaplastic and glioblastomas) can

recognized easily

infiltrate into the surrounding normal brain, for pilocytic

patient is asked to identify the pictures while

astrocytomas, complete removal is often possible.

the neurosurgeon stimulates the area thought to

say, a horse or a tree. The

—

be the speech center with low-voltage electric
New devices and less invasive techniques now make

ctirrent. In the case of a patient with motor

malignant and benign tumor resections more precise than

function impairment, the neurologist might ask

ever, with less patient trauma. One device now available

him or her to perform a simple motion, such as

at St. Luke’s Medical Center is the Stealth Computerized

opening and closing the hand or moving the toes,

Navigational System. Using CT or MRI imaging data to

while the neurosurgeon stimulates the motor area
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of the brain. If there is a disruption of either speech or

that attacks only the cancer site while sparing

motor functions while the brain is being stimulated, that

healthy tissue. This has proven effective in

area is considered critical and cannot be resected without

shrinking brain tumors that responded to no

loss of function. So for this reason, certain brain tumors

other treatment.

remain inoperable.
All of these neurosurgical innovations offer
If chemotherapy is the treatment of choice for brain

patients with benign and malignant brain tumors

cancer, a polymer wafer may be implanted during brain

a promising array of new options.

surgery. The wafer emits a regular dose of chemotherapy

35%

35%

Out of the total 103 brain/CNS tumors (including both
benign and malignant) accessioned in 2000 within the
Metro Region of Aurora Health Care, the top 10 presenting

r

symptoms included headache and balance problems

24%

with a total of 36 out of 101 patients (35%) respectively.

—I

20°
—

24 out of 101 patients (24%) presented with visual

—

16%

disturbances and weakness. 23% presented with speech
impairment, 20% with memory loss, 1 7% with vertigo,
and 16% of the patients respectively had altered alertness
and or some type of seizure activity. It is noteworthy that
some patients present with more than one symptom.
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Chemotherapy
for

brain

The most commonly

status and tumor histology. For example, younger

malignant brain tumors of

patients undergoing successful resection of tumor

the central nervous system

with high performance status and tumors other

multiforme and anaplastic
astrocytoma. Traditionally, the
Oncology of Wisconsin, SC

outcome, including age, Karnofsky performance

encountered types of

in adults are glioblastoma

Robert F. Taylor, MD

A

tumors

treatment of choice for glioblastoma
multiforme has been radiation therapy

and surgery. While prolongation of survival in adults has
been shown with those modalities, median survivals of
only 12-13 months have been reported, and recurrences
following radiation therapy are often not treatable
with additional radiation. Surgery at present is usually
reserved for diagnostic purposes, although extensive tumor
debulking can improve long-term survival compared to
more limited resections. Radiation therapy alone has
also been demonstrated to improve survival in clinical
trials, although the improvement is modest. For this reason,
the role of chemotherapy is being evaluated.

than glioblastoma multiforme do better than
older patients or those with glioblastoma diagnosed
by biopsy alone. Furthermore, many of the earlier
studies lack substantial statistical power to
reliably detect outcome differences within these
patient subsets.

Perhaps the most established role for chemotherapy
has been as an adjunct to radiation therapy. The
largest evaluation of chemotherapy in this setting,
with a META analysis, included 16 published
studies between the years 1975 and 1989 involving
more than 3,000 patients with all types of brain
tumors. This analysis showed increased survival
in patients who received chemotherapy and
radiation compared to those receiving radiation
alone. However, the only groups that benefited

One challenge for medical oncologists treating brain
tumors is to identify patients who are most likely to
respond. Current recommendations for treatment of
patients with newly diagnosed malignant glioma with
chemotherapy are based on studies that did not take into
account factors that have since been shown to influence

were those with anaplastic astrocytoma or
glioblastoma multifcriie. In general, such patients
had a good performance status, minimal residual
disease and a younger age. Those studies established
the role of chemotherapy in such tumors.
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Chemotherapy alone also has been used, either as a single

been tested. Increasingly, inhibitors with signal

agent (in most cases BCNU) or combination chemotherapy

transduction and angiogenesis as well as anti

with a three-drug regimen (PCV). In a Northern California

invasion agents are being evaluated. Molecular

Oncology Group phase-Ill trial, patients with anaplastic

markers on tumors may also help identify those

astrocytoma who were treated with the combination had a

patients who are chemosensitive and therefore

median survival of 157 weeks vs. 182 weeks for BCNU. In

would be good candidates for this approach.

patients with glioblastoma multiforme however, there was
no difference between the two. Therefore, because of the

Temozolomide is a new therapeutic agent for

ease of administration, single agent BCNU has become

brain tumors that shows considerable promise.

standard treatment for such patients.

This drug is an oral, second generation alkylating
agent, shown to have significant activity in

One interesting twist on this therapy has been the

preclinical trials. It is given as a five-day course

development of intracranial chemotherapy in the form

once a month and achieves both systemic and

of dissolvable BCNU wafers. This approach has been

intracranial levels. In a phase-Il trial of recurrent

appealing because of the inability of many chemotherapy

anaplastic gliomas, combined response and

agents to cross the so-called blood/brain barrier. BCNU

stabilization rate of 60% was found with

wafers have been placed surgically at the time of resection

temozolornide with a progression-free survival

or primary diagnosis and through a slow release mechanism

at the rate of 48% at six months. Currently, there

are allowed to penetrate the tumor substance over a longer

are phase-Il and phase-Ill trials being conducted

period of time. While the depth of invasion of BCNU

as well as trials combining this agent with standard

from the wafers is relatively limited in clinical practice,

treatments for these tumors. The results of these

interstitial pressure may allow for more extension in the

trials are obviously eagerly awaited. Temozolomide

tumor bed, and therefore this approach may be more

is very well tolerated and has few significant

effective. Unfortunately, the kinetics of drug dispersal

side effects. It can be given repeatedly without

in this setting are more difficult to predict, and variable

cumulative toxicity, and response rates in the

systemic absorption results in a more unpredictable effect

range of 30%

on the bone marrow and potentially on hematologic

trials of this agent.

—

50% are encouraging more

toxicity. It remains to be seen whether responses to this
treatment exceed more conventional BCNU trials.

Another new drug, Irinotecan or CPT-1 1, is an
analogue of the drug camptothecin. This is an

page24

Chemotherapy alone has been studied in patients who fail

intravenous medication which has been approved

first-line therapy or relapse after primary radiotherapy. It

for patients with colon cancer and inhibits a

is in this setting that most new drugs for this disease have

critical path in DNA replication and transcription.
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Early trials being conducted on malignant gliomas have

revived as an anti-cancer agent and is a potent

demonstrated a good response with CPT- 11 when used

inhibitor of angiogenesis. It has been shown

as a single agent. In one study, 60 patients with recurrent

to block angiogenesis generated by endothelial

gliornas were treated weekly for four weeks followed by

growth factor and this characteristic makes it

a two week rest period, and partial responses were seen

appealing in gliomas. A phase-Il trial using

in 10 of the 49 evaluable patients with glioblastoma

thalidomide for patients with recurrent high

multiforme. Toxicity was minimal, suggesting that more

grade gliomas has shown favorable responses

studies are worthwhile. Currently, new phase-I and

and, based on this data, a phase-Ill trial is

phase-Il trials are being conducted.

being opened to evaluate patients with recurrent
disease. In addition, phase-TI trials are now being

Matrix metalloproteinases are a family of enzymes

evaluated to combine thalidomide with carboplatin

responsible for normal turnover and remodeling of the

or BCNU in treatment of recurrent gliornas,

extra-cellular matrix. Those enzymes are required for

since thalidomide has virtually 110 additive

tumor angiogenesis and invasion. Inhibitors therefore

hernatologic toxicity.

would be expected to be active in preventing dissemination
and growth of such tumors. One such drug, marimastat, is

Despite all of the encouraging trials outlined

being evaluated in a phase-Ill trial for patients with newly

above however, the treatment of gliornas with

diagnosed glioblastoma multiforme. This study randomized

chemotherapy remains a challenge. Several

patients to receive marirnastat or a placebo following

negative studies have been published over the

external radiation. Results are expected soon and

past couple of years, and high response rate

hopefully will show promise in this disease.

chemotherapy trials remain to be reported.
Future improvements in survival for this tumor

Angiogenesis inhibitors have been looked at for a variety

will depend on identifying patients with

of tumors including brain tumors, and while the results are

chemosensitive disease and then combining

not as enthusiastic as the preclinical trials have suggested,

drugs that have complementary activity without

these studies have shown efficacy in brain tumors. One

overlapping toxicities. Clearly, research in this

of the most promising of these agents is thalidomide.

area will take many years to develop, but the

Thalidomide is a drug most commonly known by the lay

pace of new drug development is quickening

public for its effect on newborns. When taken by pregnant

in this disease and optimism concerning new

women it caused severe birth defects with short limb

discoveries remains.

syndrome, a side effect that ultimately led to its removal
from the market. However, this drug has recently been
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whole brain radiation therapy. Patchell also showed

Lastly, there are a number of benign brain tumors

radiation therapy added to a solitary resection decreased

including meningiomas, pituitary adenomas,

by 50% the rate of distant brain progression. A recently

acoustic neuromas, etc. The treatment options

presented randomized trial from Rhode Island in patients

for these tumors depend on a number of factors

with 1 to 3 brain metastases has shown an increase

which must be individualized.

in local control from 60 to 90% with Gamma Knife
radiosurgery added to whole brain radiation. This study

In conclusion, brain tumors vary in their histology,

also found a 50% reduction in distant brain failure if

location, behavior, and overall prognosis. A wide

whole brain radiation is used with radiosurgery.

variety of treatment options are available including
surgery, 3-D conformal radiotherapy, intensity

Astrocytomas are the most common primary malignant

modulated radiotherapy, Gamma Knife and linac

tumor of the brain. In fact, 50% of all primary brain

radiosurgery, chemotherapy, and hormonal

tumors are astrocytomas and 75% of these are glioblastoma

treatments, for this reason, a multidisciplinary

multiforme or grade 4 astrocytomas. Surgery is the primary

evaluation is needed to determine the most

mode of therapy for astrocytomas with post-operative

beneficial course of treatment in any

radiation or radiation with chemotherapy being the standard

one individual.

of care. The radiation delivered is 3-dimensionally
conformal with computer planning based off of fused
MRI and CT scans. The RTOG is currently studying the
role of radiosurgery as a boost for high grade gliomas
less than 4 cm in size.
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Pathology
of

brain

tumors

Tumors of the nervous system

Anaplastic Astrocytoma:

include a large variety of

This astrocytorna corresponds to WHO grade III.

neoplasms including benign

The progression of an anaplastic astrocytoma to

and malignant tumors of the

glioblastoma is a key prognostic factor. The time

brain, intracranial peripheral

interval varies considerably with a mean of

nerves, meninges, pituitary and

2 years. The presence of an oligodendroglial

pineal gland and the skull.

component is
associated with

Jorge Pellegrini, MD

4t4i.

‘d
,

Department of Laboratory Medicine, Great Lakes Pathologists (GLP)

a significant
The following descriptions correspond to the most

increase in

common tumors encountered in the practice of pathology.

survival (>7
years). There

Diffuse Astrocytoma:
This astrocytorna corresponds to the WHO grade II. The
histologic subtypes correspond to fibrillary, gemistocytic

is an increased survival rate in younger patients,
high preoperative Karnofsky score and gross
total resection.

and protoplasmic astrocytomas.

The mean survival time after surgical intervention is in
the range of 6

—

$ years with marked individual variation.

A younger age and gross total tumor resection are considered
predictive of delayed recurrence and progression. It is
generally acknowledged that diffuse astrocytomas WHO
grade II with a significant fraction of gernistocytes tend

Gil obiasto ma:
This astrocytorna and its variants correspond to
WHO grade IV. Despite extensive clinical trials,
individual prediction of clinical outcome has
remained an elusive goal. Glioblastomas are
among the
most malignant

to undergo malignant

human

progression more
rapidly than the ordinary
fibrillary astrocytomas.

neoplasms with
a mean total
length of
disease of less than one year in primary
glioblastomas. Several studies suggest that
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the presence and extent of necrosis correlates with a poor

Oligodend tog lioma:

clinical outcome. There is some evidence that complete

This tumor corresponds histologically to WHO

resection favors longer survival and that young patients

grade II. The most frequent genetic alteration

(under 45 years) have a considerably better prognosis than

as determined by loss of heterozygosity (LOH)

the elderly. Among other types of glioblastomas, although

analysis is LOH on the long arm of chromosome

giant cell glioblastomas carry a poor prognosis, some

19 (ranging from 50% to more than 80% of cases)

reports indicate that the clinical outcome is somewhat

and LOH on the short arm of chromosome 1.

better than that of the ordinary glioblastoma.

Median post-operative
survival time ranges

.i.

i;4

Pilocytic Astrocytoma:

from 3 to 5 years of

This astrocytoma corresponds to WHO grade I. As a

all histologic grades.

group, these tumors are slow growing masses, which at

The mean survival

any point in their evolution, may stabilize or even regress.

rate of grade II

Rarely, pilocytic astrocytornas can be anaplastic. Most of

oligodendrogliomas vary from 38% to as high

these tumors are associated with growth and aggressive

as 76% 5-year survival and from 19% to as

behaviors but others are cured by surgical excision with

high as 59% 10-year survival. These tumors

or without adjunctive radio or chemotherapy.

generally recur locally. Malignant progression
on recurrence is not uncommon, although it

Pleomorphic Xanthoastrocytoma:

is considered less frequent than in diffuse

This tumor corresponds histologically to WHO grade II.

astrocytomas. Features associated with a more

for lesions with significant mitotic activity and/or

favorable outcome include younger age at

with areas of necrosis, the designation of pleomorphic

operation, frontal location, post-operative

xanthoastrocytorna with anaplastic features may be used.

Karnofsky score, lack of contrast enhancement
on neuro-irnaging, macroscopically complete

The overall survival has been estimated as $ 1% at 5 years

surgical removal and irradiation after partial

and 70% at 10 years. The extent of resection of the

tumor resection.

original tumor mass appears to be the most significant
predictive factor, followed by a low mitotic index. Mitotic

Anaplastic Oligodendroglioma:

activity is the only independent predictor of survival.

These tumors correspond histologically to

Necrosis, although significantly associated with survival,

WHO grade III. The reported median survival

was not an independent predictor.

rate is 3.9 years and the 5 and 10 year survival
rates are 41% and 20% respectively. Most
patients die from local tumor recurrence.
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Occasionally, patients may develop metastasis via the

survive longer on average than patients with

CSF or even systemic metastasis. A rare complication

anaplastic oligodendrogliornas and patients

of oligodendroglioma and anaplastic oligodendrogliorna

with anaplastic oligoastrocytomas have a better

is leptorneningeal oligodendrogliomatosis. Anaplastic

prognosis than patients with pure anaplastic

oligodendrogliornas that have allelic losses on lq and 19q

astrocytomas. In addition, there is evidence

are typically sensitive to procarbazine, CC/VU and

that glioblastomas with an oligodendroglial

Vincristine (PCV) chemotherapy. In addition, the presence

component are associated with longer survival

of ring enhancement on initial neuroimaging has been

rates than classical glioblastomas.

reported to correlate to a lack of response to PCV.

Other Mixed Gliomas:
Oil go a St r o cyt o ma:

These tumors are very rare and only occasional

These tumors correspond histologically to WHO grade II.

cases have been reported.

The molecular genetics are more heterogeneous than those
characteristically associated with pure oligodendrogliomas.

Ependymomas:
These tumors correspond histologically to WHO

The median survival rate is 6.3 years and the reported 5

grade II. Four histopathologic variants have

and 10 year survival rates are 58% and 32% respectively.

been described, i.e., cellular, papillary, clear cell,

Factors associated with longer survival include a younger

and tanycytic.

age at surgery, gross total tumor resection and post
operative radiation therapy. From a clinical viewpoint,

Generally, clinical outcomes in children appear

it has become increasingly important to differentiate

to be significantly worse than in adults. Ages

between oligoastrocytomas and “pure” astroglial tumors

below 3 years, anaplastic histopathological

because oligoastrocytomas, like oligodendroglial tumors,

features, incomplete tumor resection, and evidence

appear to respond favorably to chemotherapy such as PCV

of CSF metastases are indicators of a poor
outcome in children. Survival rates at 5 and 10

Anaplastic Oligoastrocytoma:

years are 57% and 45% respectively according

These tumors correspond histologically to WHO grade III.

to one series, on adult patients. Supratentonial

The prognosis for these tumors is relatively poor, although

ependymomas are associated with better survival

still considerably better than for patients with a classic

rates compared to posterior fossa neoplasms

glioblastoma. The median survival rate is 2.8 years

and spinal ependymomas show a significantly

and the 5 and 10 year survival rates are 36% and 9%

better outcome compared to cerebral lesions.

respectively. Survival rates increase when the patients

Cerebrospinal dissemination indicates a

are treated by surgery, irradiation and PCV chemotherapy.

poor prognosis.

Patients with anaplastic oligoastrocytomas
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Anaplastic Ependymomas:

Choroid Plexus Tumors:

These tumors correspond histologically to WHO

Choroid plexus papillomas correspond

grade III. Several studies indicate that there is no

histologically to WHO grade I. Choroid

correlation between the survival of patients and classical

plexus carcinoma corresponds to WHO grade III.

histopathological signs of malignancy observed. A

Histologically, choroid plexus tumors are divided

relationship with survival rates only becomes evident

into papillomas, carcinomas and atypical choroid

when high cell density and brisk mitotic activity were

plexus papillomas. The papillomas can be

considered as independent variables.

cured by surgery with a 5 year survival rate of
100%. The carcinomas grow more rapidly and

Myxopapillary Ependymomas:

have a less favorable outcome with a 5 year

These slow growing tumors have a favorable prognosis

survival rate of 40%; meningeal dissemination

and correspond to WHO grade I. Anaplastic variants are

and systemic metastases may occur. Gross total

virtually unknown. This entity shows a good outcome

resection appears to be the treatment of choice

with greater than a 10 year survival rate after total or

for carcinomas. The poor prognosis of these

partial resection. Late recurrence and distant metastases

tumors correlates with mitosis, necrosis, brain
invasion and decreased expression of $100

are very uncommon and subarachnoid dissemination has

protein. Carcinomas also may produce frank

occasionally been observed.

metastases along CSF pathways.

Subependymomas
Meningeal Tumors:

These tumors correspond histologically to WHO grade I.
Subependymomas carry a good prognosis and surgical
removal is usually curative.

Most meningiomas are benign and can be
grouped into WHO grade I. Certain histologic
subtypes are associated with a less favorable
clinical outcome and correspond to WHO
grade II and III (please refer to table below).

Meninglomas Grouped by Likelihood of Recurrence and Grade
Meningiomas with tow risk of recurrence and aggressive growth

Meningiomas with greater likelihood of recurrence and/or aggressive behavior
Clear cell meningioma (intracranial)
WHO grade II

Meningothelial meningioma
Fibrous (fibroblastic) meningioma

WHO grade I
WHO grade I

Chordoid meningioma

Transitional (mixed) meningioma
Psammomatous meningioma

WHO grade II

WHO grade I
WHO grade I

Rhabdoid meningioma

Angiomatous meningioma
Mycrocystic meningioma

WHO grade I

Papillary meningioma

WHO grade Ill
WHO grade Ill

WHO grade I

Anaplastic (malignant) meningioma

Secretory meningioma

WHO grade Ill

WHO grade I

Lymphoplasmacyte-rich meningioma
Metaplastic meningioma
Atypical meningioma

WHO grade I
WHO grade II

WHO grade I

Meningiomas of any subtype or grade with high proliferative index and/or brain invasion
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Mutations in the NF2 gene are detected in up to 60%

Neurofibroma (WHO grade I)

of sporadic meningiornas. The major clinical factor in

This tumor is usually solitary and indolent with

recurrence is the extent of resection, which is influenced

a favorable prognosis. Multiple neurofibrornas

by the site of occurrence, attachment to intracranial

are the hallmark of von Recklinghausen

structures and the age of the patient. In one series 20% of

Neurofibromatosis (Nf 1).

gross totally resected benign meningiomas recurred within
20 years. Overall, tumor grade provides the most useful

Hematopoletic System Tumors

histological predictor of the likelihood of recurrence.

The increasing incidence of CNS malignant

While benign meningiomas have recurrence rates of about

lymphomas over the past two decades can be

7

—

20%, atypical meningiomas recur in 29

—

40% of cases

and anaplastic meningiomas have recurrence rates of
50

—

78%. The absence of progesterone receptors, a high

attributed by the HIV- 1 epidemic, since up to
10% of terminal AIDS patients develop an
Epstein-Barr virus (EBV) that is associated

mitotic index and higher tumor grade were significant factors

with malignant cerebral B-cell lymphoma. The

in shorter disease-free intervals in meningiorna patients.

vast majority of primary CNS lymphomas are
malignant B-cell lymphomas which unlike their

Tumors of Cranial and Peripheral Nerves

systemic counterparts, carry a poor prognosis.

Tumors of the cranial and peripheral nerves include a

Rare lymphornas involving the nervous system

wide range of histopathological features and associated

include T-cell lymphomas, plasmacytorna,

clinical characteristics. These tumors frequently occur in

angiotropic lymphoma and Hodgkins disease.

the setting of familial cancer syndromes, in particular the
neurofibromatoses. Two of the major clinicopathological

A variety of histiocytic tumors and histocytoses,

entities include:

more commonly encountered at extracranial
locations, may also arise within the CNS.

Schwannoma (WHO grade I)
Schwannomas can occur anywhere in the peripheral
nervous system but intracranially its most frequent site
is the vestibular division of the eighth cranial nerve.
Surgical resection is usually the curative modality for
this benign, slow growing neoplasm. (See photo on right)
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Psychiatric Manifestations
of

central

nervous

The presence of a psychiatrist

‘:

a) seizures

—

especially if

of new onset in an adult and if they are focal or

with a brain tumor is often

partial, b) headaches

—

especially if new onset,

necessary. In fact, reports

generalized and dull, increasing in severity, or

of psychiatrists being the

positional or nocturnal, c) nausea and vomiting

brain tumor in a patient are

and Psycho-oncology Services

a brain tumor

tumors

in the care of a patient

first physician to suspect a

Jeffrey J. Knajdt, MD, Medical Director
Vince Lombardi Cancer Counseling

system

not uncommon. Brain tumors
command special vigilance and

—

especially in conjunction with headaches, d)
sensory changes

—

especially visual changes,

auditory changes, or vertigo, and e) focal
neurologic signs and symptoms.

attention as patients develop neuropsychiatric symptoms
in

50%1)

of cases and one study reported the incidence

Modifiers of Neuropsychiatric

of symptoms as high as 78%.° Psychiatric and behavioral

Symptoms

symptoms include psychosis, mood disorders, anxiety,

A number of factors can increase the chances

delirium and personality changes.

that a patient with a central nervous system
tumor develops psychiatric symptoms. These risk

Etiologies of brain tumors may be from a primary

factors include: ti)

intracranial mass or may be representative of a metastatic

pressure, b) lower level of premorbid functioning,

process from an anatomically distant site. The most

c) presence of a pre-existing primary psychiatric

common tumor types of primary lesions (in order of

disorder, d) rapid rate of tumor growth, e) presence

frequency) include gliomas, meningiomas and pituitary

of multiple metastatic lesions, f) tumor type

adenomas. Metastatic CNS tumors (also in order of

especially if meningioma with translobal

frequency) originate from the lung, breast, kidney

extension, g) laterality (REFER TO TABLE 1),

and gastrointestinal system

and h) location (REFER TO TABLE 2).

(3), 4)

(5)

a) increased intracranial

B

—

Role of Psycho-Oncology in Diagnosis
The occurrence of one or more of the following signs
and symptoms in a known psychiatric patient or in a
patient presenting for the first time with psychiatric

Table 1: Laterality of CNS Tumor
Location

Common Psychiatric Symptoms

Right-sided tumor

Mania, confusion

Left-sided tumor

Depression, apathy

symptoms should heighten the index of suspicion for
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Table 2: Location of Central Nervous System Tumor

Location

Common Psychiatric Symptoms

• Frontal lobe

Disinhibition; inappropriate sexual behavior; irritability; poor judgement; apathy; depression

• Temporal lobe

Visual, olfactory, tactile, auditory hallucinations; affect is not flattened; mood changes; anxiety

• Parietal lobe

Psychiatric symptoms not common and if present are similar to depression

• Occipital lobe

Psychiatric symptoms not common and if present are visual hallucinations

• Diencephalon (3rd ventricle,

3rd ventricle: flat affect, emotional withdrawal, akinetic mutism
Hypothalamus: disrupted eating behavior ranging from hyperphagia to anorexia; hypersomnia

thalamus, hypothalamus)

• Corpus callosum

Depression

Treatment

in relieving distress and maximizing quality of

Psychotherapy with patients with neuro-oncologic problems

1ife.21 Psychopharmacologic agents can be useful

can be challenging, yet very helpful if facilitated by a

in the treatment of symptoms of agitation,

well-seasoned therapist. Holland identified key issues

depression and anxiety. While placebo-control

most brain tumor patients face that can be addressed

studies about the use of psychiatric medications

in psychotherapy including concerns about disability,

in patients with brain tumors are povertous,

dependency, disruption, disfigurement, and death. (6)

clinical experience has shown that use of these

Psychotherapy is generally supportive in nature but also

medications is critical in symptom management.

involves elements of crisis intervention and solution-

TABLE 3 represents a summary of some

oriented approaches. Relaxation therapy can be useful

key points to consider when administering

as an adjunct to analgesics for headache pain control.

psychotropic medications to this population.

Encouraging patients to keep a diary of their sessions

The totality of symptoms seen with a brain tumor

can help those struggling with memory problems so

is a medical and psychiatric matrix that demands

that therapy does not become yet another frustrating

special attention. For patients who are plagued

experience lost to tumor-related amnesia. Other purposes

by psychiatric symptoms secondary to a CNS

of therapy include work involving anticipatory bereavement,

tumor, multiple benefits are attainable when

family support, and dialoguing with the patients the

consultation is arranged with a professional

benefits that psychotropic medications can provide

with clinical expertise and experience in this
complex psycho-oncological presentation.
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Table 3: Key Points to Consider in the Use of Psychotropic Medications in Neuro-Oncological Patients

1) Higher risks for side effects exist, so smaller doses of
medications may be needed. The phrase “Start low
(in dosing) and go slow (when titrating)” highlights
this precautionary measure.

6) Even though almost all neuroleptics can lower seizure
threshold, drugs such as haloperidol and some of the
newer atypical anti-psychotics are excellent “first choices”
for agitation and confusion, anxiety, or some cases of
insomnia. Note that haloperidol, when administered
intravenously, is generally devoid of extrapyramidal
side effects.

2) Limit or avoid the use of agents with anticholinergic
properties (i.e., tricyclic antidepressants, low potency
neuroleptics) secondary to risk of delirium.

7) Treatment of depression, cognitive slowing, or fatigue
can be approached with the use of psychostimulants
(i.e., methylphenidate, dextroamphetamine) administered
twice per day at 7 or $ a.m. and again at 12 or 1 p.m.

3) Cautious use of benzodiazepines is suggested because
of risk of delirium as well as paradoxical reactions or
disinhibition syndrome.
4) Procarbazine has monoamine oxidase inhibitor
activity and concomitant use with antidepressants
or psychostimulants is contraindicated.

8) Treatment of depression is preferred with SSRI’s or
atypical/newer antidepressants but a psycho-oncological
consultation is suggested. The unwanted properties
of anticholinergic side effects seen with paroxetine,
the theoretical decrease in seizure threshold with
bupropion, and other numerous drug-drug interactions
are examples of events that can be avoided with the
help of a psycho-oncology referral.

5) High dose steroids, especially in excess of 60-80 mg
of prednisone per day (or its equivalent) can cause
symptoms ranging from anxiety or depression to
severe psychosis or mood instability. Neuroleptics
(and benzodiazepines in a few cases) are preferred
to counteract this iatrogenic event.

References
1) Price T, Goetz K. Lovelt M. Neuropsychiatric aspects of brain tumors. In: Yudofsky S. Hales R. eds. Textbook of Neuropsychiatry. Washington, DC: American Psychiatric Press; 1997.
2) Passik S. Ricketts P. Central nervous system tumors. In: Holland JCB. ed. Psycho-oncology. New York, NY: Oxford University Press; 1998.
3) Nelson D. McDonald J. Lowell L, et al. Central nervous system tumors. In: Robin P, ed. Clinical Oncology. Philadelphia. PA: WB. Saunders Company; 1993.
4) Moore D, Jefferson]. Brain tumors. In: Moore D. Jefferson J, eds. Handbook of Medical Psychiatry. St. Louis, MO: Mosby-Year Book, Inc.: 1996.
5) Reichman W. Neuropsychiatry and behavioral neurology. In: Kaplan H. Sadock B. edo. Comprehensive Textbook of Psychiatry/VI. Baltimore. MD: Williams & Wilkins; 1995.
6) Holland JCB. Psychological aspects of cancer. In: Holland JF. frei E, eds. Cancer Medicine. Philadelphia: Lea and Febiger: 1996.

As displayed in the graph, benign brain/CN5 tumors were more
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prevalent at AHC-Metro in the year 2000, accounting for about 57%
of the cases included in the PCE study (59 cases out of a total of 103

57

•

Malignant

•

Benign

cases). As reported through the CBTRUS, malignant brain tumors are
the most frequently reported. The overall incidence rate for primary
brain and central nervous system tumors was 12.7 per 100,000
person years (adjusted using the year 2000 standard).
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Five Year Relative Survival for Brain and Other Central Nervous System Tumors
80%
70%

50%

The graph on the left represents relative survival of malignant brain and CNS tumor
patients with combined stages of diseases who were reported between 1988 and 1992.
The results demonstrate a comparable outcome curve between Aurora’s Metro patients*

40%

compared to those reported nationally to the Surveillance, Epidemiology and End Results

60%

(SEER) program of the Nd.

30%
20%

*excludm spinal and cerebral meningeal tumors

10%
0
Year 1

Year 2

Year 3 Year 4

Year 5

Of the five prior medical conditions collected in the PCE,
a significant percentage (40%) of Aurora patients had a
history of hypertension; followed by 16% who carry
a history of diabetes.

In aggregate, the largest number of brain/CNS cases
seen in AHC-Metro Region have a size of less than
40mm. (Includes both benign and malignant cases.)
Comparison data through CBTRUS and/or NCDB is
not available at this time.
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Here within AHC-Metro, tumors located
in the meninges accounted for the largest
majority of the CNS tumors with
29%
20

19

(29 cases) (including both benign and
malignant), with tumors in the cerebru
m
at 22% (21 cases), 20% as other

E

-

•

(including all lobes and overlapping

-

lesions) and acoustic nerve tumors

-

5
-

a

--

5

——

:

1

-

3

with 20% (19 cases) coming in second
and third respectively.

1

I % Oligodndrogliom
1% Crniopharynioma
1%
According to the CBTRUS the most
frequently

20%

,J

8°,

reported histology is a meningioma

2% pendymoria
2%

35%

7% Neurilemrroma

I

3 LymphorEa

(predominately a benign tumor), which
accounts tor over 25% of all brain/C
NS
tumors, followed by glioblastomas
and
astrocytomas. Here in AHC-Metro during
the year 2000, meningiomas acco
unted
for 35%, acoustic neuromas 24%,
and
glioblastomas 18% of our BrainJ
CNS
tumors (this includes only those cases
that qualified for the 2000 PCE).
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Oncology Research
projects

The year 2001 has been

Carol Tutino, BSN, CCRC
Clinical Research Department

and

accrual

While clinical trials that focus on treatment

a very exciting year for

options for our patients continue to be the

Aurora Health Care, as

majority of the studies at Aurora Health Care,

a new department had been

the year 2001 has brought different types of

established late last year.

oncology studies as well. The SELECT trial is

This was the Clinical Research

looking at the use of Selenium and Vitamin E

Department and after a very long

for the prevention of prostate cancer. Two new

nationwide search, a new Director

genetic studies for the detection of breast cancer

was named to head up this endeavor.

include the use of saliva, looking for c-erB-2 and

Dr. Bryan J. Tucker came to Aurora from San Diego

a study that looks at actual breast cancer tissue

in October of 2000, and while the department is a

for the discovery and evaluation of biomarkers.

system-wide department, the majority of the studies

Some additional new studies include one that is

it is supporting are focused in the Metro Region.

looking at the treatment of cancer cachexia and
one looking at quality of life issues for breast

The number of oncology studies supported by the Clinical

cancer women undergoing chemotherapy.

Research Department or by private physician groups have
increased significantly over the last couple of years and

Bringing cutting edge technology and new

include all of the oncology treatment areas. Aurora Health

treatment options to our patients is a very

Care continues to support six major oncology cooperative

rewarding result of participating in clinical

groups, which include National Surgical Adjuvant Breast

research. As we continue to build new

Program (NSABP), the Eastern Cooperative Oncology

relationships with study sponsors, the number

Group (ECOG), the Cancer and Leukemia Group B

of options available for our oncology patients

(CALGB), the Radiation Therapy Oncology Group (RTOG),

will continue to grow.

the Sarah Canon Cancer Network, and the American
College of Surgeons Oncology Group (ACOSOG). In

For information regarding oncology studies

addition, patients have access to numerous genetic, quality

or who to contact, please call Carol Tutino

of life, pharmaceutical and cancer prevention clinical trials.

at 414-649-5526.
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Vince Lombardi
cancer

clinics

The Vince Lombardi Cancer

sites are putting together a special binder for

Clinic’s (VLCC) approach

patients that will contain the information needed

is to fight cancer on all

as they journey through the various stages of

fronts with education,

cancer care from initial diagnosis to treatment

prevention, diagnosis,
treatment and support. By

and then post treatment. The binder will be
available in 2002.

offering all-encompassing care
through a coordinated team effort,

Patty Abella, RN, MSN
Outpatient Cancer Services

patients and families can have their

Another way the Clinics support their patients
and families is through participation in research

cancer care needs met through the Clinics, which are

protocols. Currently, there are more than 30

conveniently located throughout southeastern Wisconsin:

research protocols available to patients with
different cancer diagnoses such as breast,

Vince Lombardi Cancer Clinic
Vince Lombardi Cancer Clinic
Vince Lombardi Cancer Clinic
Vince Lombardi Cancer Clinic
Vince Lombardi Cancer Clinic
Vince Lombardi Cancer Clinic
Vince Lombardi Cancer Clinic
Vince Lombardi Cancer Clinic
Vince Lombardi Cancer Clinic

—

—

—

—

—

—

—

—

—

St. Luke’s Medical Center

prostate, colon, lung, renal and melanoma.

St. Luke’s South Shore
Aurora Sinai Medical Center

Every effort is always made to coordinate care

Slinger

through a patient’s local VLCC or hospital. If

West Bend

specialized cancer services are required, patients

Kenosha

have access to the tertiary hospital, St. Luke’s

Lakeland Medical Center

Medical Center (SLMC). The VLCC at SLMC

Manitowoc

puts extensive effort into supporting unique,

Sheboygan

leading-edge therapies such as Immunotherapy
and Autologous Bone Marrow Transplantation.

The Vince Lombardi Cancer Clinics continually work
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40

together to improve service to patients and their families.

The VLCC at SLMC also supports all apheresis

A current project underway is to improve patient and

needs of cancer patients as well as of any other

family knowledge and understanding of chemotherapy

patients in the hospital that require this service.

side effects. A group of registered nurses from all of the

The dedicated staff provides this service seven

regional

activities

days a week, 24 hours a day to encompass any emergent

The community link to all of the Vince

needs. This is a very unique program in that most

Lombardi Cancer Clinics is a toll-free hotline

hospitals contract from their local blood center. Recently,

(800-252-2990). Hotline staff put callers in

the American Association of Blood Banks recertified

touch with accurate answers to a variety of

the VLCC apheresis program.

cancer questions ranging from prevention
and detection concerns to how to access the

Supporting the needs of cancer patients also requires a

latest treatments, research protocols and area

dedication to recruiting and training future caregivers.

support groups.

Nationally, there is a shortage of caregivers and this
is especially true of a specialty such as oncology. The
Vince Lombardi Cancer Clinics and staff are committed
to providing positive mentoring and learning experiences
for students enrolled in university and technical programs
as well as high school students enrolled in an INROADS
program. The goal of the INROADS program is to place
students of color in businesses, such as hospitals, and
prepare them for corporate and community leadership.

regional

activities

page4

Community
outreach

activities

Our community outreach
efforts focus on educating

Cancer Society Relay for Life in Washington

people in Eastern Wisconsin

County, and the Susan G. Komen Breast Cancer

about the facts that increase

Foundation-Race for the cure in Milwaukee

the risk of developing cancer,

County were two large events that rallied our

identifying ways to reduce
their risk, and emphasizing the
Marija Weidman, RN, MSN

national patient advocacy groups. The American

patients and staff around a very significant
message

—

that of life!

importance of early detection.

Business and Market Development

One method of reaching that goal

Harry Belafonte, entertainer and longtime

is via our Vince Lombardi Cancer Hotline. The hotline

activist, as well as a prostate cancer survivor,

is a toll free service (800-252-2990) to respond to

was the keynote speaker at Aurora Health Care’s

phone inquires about cancer from consumers, patients,

Second Annual Men’s Health Conference in

physicians and other health professionals. Hotline staff

September 2001. The event was sponsored by

put callers in touch with accurate answers to a variety

a number of organizations, including Buddies

of cancer questions. Written information is often mailed

Against Prostate Cancer, founded by radio

to the caller or they are referred to one of the Vince

personality Bob Reitman, former Brewers pitcher

Lombardi Resource Libraries located in each of our Vince

Ken Sanders and businessman Gary Grunau.

Lombardi Cancer Clinics. The libraries offer computer

Mr. Belafonte began his day seeing patients at

access along with an extensive array of the latest videos,

the Vince Lombardi Cancer Clinic at St. Luke’s

books and pamphlets that can be checked out.

Medical Center and then visited the Gamma
Knife Center and Immunotherapy Program.

Another method of outreach is that we continue to let

Speaking at a press conference in front of the

our communities indicate the outreach activities that

VLCC, Belafonte, Reitmen and Sanders urged

best meet their needs. These activities have included our

men to see their doctors, while discussing the

cancer experts presenting information at local churches

commonalties shared among men who have

and businesses as well as partnering on “getting the

survived prostate cancer.

message out” at larger events with local/regional and/or

page4
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At the Sheraton Hotel, Belafonte spoke of his life in
entertainment and his worldwide travels to advocate
for human rights causes and health concerns. His
passion and humor held the attention of an audience
of approximately $00.

In addition to Belafonte’s poignant speech, the Men’s
Health Conference included a talk on male breast cancer
by survivor and author Michael Samuelson, as well as
educational booths focusing on a variety of men’s
health issues including heart care, colon cancer, stroke
prevention, mental health issues and sleep disorders.

4
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Cancer
support

Cancer support groups are
for people whose lives have
been touched by cancer.
They provide education, a
sharing of experiences and
inspiration. These groups, for
many, are critical components
Barbara K. Clinkenbeard, Ms, NP

to comprehensive cancer treatment.

Vince Lombardi Cancer Counseling Center

I

groups

Psycho-educational groups,

A Time to Grieve
Third Thursday of each month from 1:30 p.m.
to 3:00 p.m. at Aurora Health Center in Slinger.

The ABMT Support Group
For people who have undergone an autologous
bone marrow transplant. Held at St. Luke’s
Medical Center. Call the Vince Lombardi
Hotline at 414-649-7200 for meeting dates
and times.

Breast Friends The Breast
Cancer Support Group
-

for example, play important roles in focusing on
information and improving compliance with treatment.
Some studies have shown brief structured interventions
not only can improve mood and coping but immunity
as well. Several studies have focused on the correlation
between the adequate training of the group facilitators and
the effectiveness of the groups themselves. Our particular
program incorporates general support group facilitator
training, but also focuses on introducing group leaders
to the art and science of the field of psycho-oncology
as part of their education.

The first support group facilitator training was held
Friday, June 22, 2001. Carol Ott, PhD was the course
facilitator. This was a day-long training session in
which Dr. Knajdl and Barbara Clinkenbeard, MS, NP
incorporated principles of psycho-oncology into
the training. There is no charge to the staff for this
psycho-oncology support group facilitator training
that will be held biannually.
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for women who have been diagnosed with breast
cancer, their families and friends. Meets the
last Tuesday of each month from 6:00 p.m. to
8:00 p.m. at St. Luke’s Medical Center in the
Cancer Counseling Center.

Care for the Caregiver
Support Group
for individuals who care for an aging or disabled
individual. Every other Thursday from 10:00 a.m.
to 11:30 am. at West Allis Memorial Hospital.

Every Day Counts
First Wednesday and third Tuesday of each month
from 1:00 p.m. to 2:00 p.m. at Aurora Health
Center in Slinger.

Experiencing Grief
Recently Widowed

For people who have lost a loved one and are
going through the grieving process. Meets
Tuesdays for eight weeks from 1:00 p.m. to
3:00 p.m. or 7:00 p.m. to 9:00 p.m. at St. Luke’s
Medical Center. To register call 414-328-6280.

I
Kids’ Connection

Rebound

To help children ages 5 through 18 cope when a parent
or loved one has cancer. This group is offered periodically
and meets for four weekly sessions from 6:00 p.m. to 7:30
p.m. at St. Luke’s Medical Center in the Immunotherapy
Conference Room. Registration by custodial parent or
guardian is required.

Rebound is a highly personalized and intimate
support group for women who have recently been

Living Through Loss Support Group
Designed to help people move through the grieving
process. First and third Tuesday of each month from
10:00 a.m. to 11:30 a.m. or 6:00 p.m. to 7:00 p.m.
at West Allis Memorial Hospital.

Look Good... Feel Better
For people who are undergoing cancer treatment. This
program presents techniques to help people gain control
and even triumph over the cosmetic side effects of treatment.
Offered six Mondays per year from 1:00 p.m. to 4:00 p.m.
Call 414-649-7200 for dates and pre-registration.

Make Today Count
For people with cancer or other life-threatening illnesses
and their families. This group is a cooperative effort of
St. Luke’s Medical Center and the American Cancer
Society. Meets the fourth Thursday of each month January
through October and the third Thursday of November and
December (to accommodate the holidays) from 7:00 p.m.
to 8:30 p.m. at St. Luke’s South Shore, 5900 South
Lake Drive, Cudahy.

Newly Diagnosed With Breast Cancer
This support group meets weekly for six weeks and
is offered four times a year. For more information
call 414-649-7200.

Ovarian Cancer Awareness Group
For women who are at risk for or have been diagnosed
with ovarian cancer. First Tuesday of each month from
6:30 p.m. to 8:00 p.m. at St. Luke’s Medical Center.

Positive People
Mutual support, socializing, advocacy, and education for
persons with cancer, their families and friends is provided.
It also offers an opportunity to share problems and
concerns encountered while coping with this disease.
For more information call 414-328-7405.

—

Living with Breast Cancer

diagnosed with breast cancer. The rebound
program works with breast cancer patients to
address the physical and emotional adjustments
they face during breast cancer treatment.
Rebound meetings combine education on
health-related topics, along with group sharing
of feelings and experiences related to breast
cancer. All information is strictly confidential.
Meets Wednesdays from 4:30 p.m. to 6:30 p.m.
at Aurora Sinai Medical Center’s Behavioral
Health Clinic.

Refocusing On Hope A Support
Group For People With A Primary
Brain Tumor
-

For people who have been diagnosed with
primary brain tumors, their families and friends.
For information on the meeting location, dates
and time, please call the Vince Lombardi
Cancer Hotline at 414-649-7200.

Us Too! The Prostate Cancer
Support Group
-

For men who have experienced prostate cancer
and their families and friends. Meets the first
Wednesday of each month from 7:00 p.m. to
8:30 p.m. at St. Luke’s New Berlin Health Care
Center, 14555 West National Avenue, New
Berlin, in the Community Events Room.

Women Supporting Women
Breast Cancer Survivor Group
For women of color who have experienced breast
cancer. Meets the third Saturday of every month
from 11:00 am. to 1:00 p.m. at House of Peace,
17th and Walnut.
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Your Caring Connection

Pastoral Care Program

For patients experiencing cancer, their families and
friends. Meets the second Monday of each month from
6:30 p.m. to 8:00 p.m. at St. Luke’s Medical Center in
the Cancer Counseling Center. For more information,
please call the Vince Lombardi Cancer Hotline
at 414-649-7200.

Future Goals for the Support Groups
1) Support group held during the day for individuals
who are unable to attend evening groups.
2) Training facilitators of support groups to bring
specific attention to psychosocial issues associated

Reverend Marcia Marino
Director Pastoral Care Program

with the stage of the disease and assess “readiness”

Chaplains are professionally trained to provide

of participants for the support group and whether

spiritual and emotional support to patients and

psychotherapy (individual, family, or group) and

families who are dealing with cancer. Referrals

referral to a psychiatric professional may be a

are received from patients, families, physicians,

more appropriate and effective intervention.

nurses, social workers, community clergy,

3) A six-week ongoing newly diagnosed breast cancer

nursing assistants and volunteers.

group is in the developmental stage. We plan to use
the audio resource program “The Cancer Survival Tool
Box.” The first meeting is to be announced and will
be held in the Cancer Counseling Center at St. Luke’s
Medical Center.

hospitals, chaplains support patients of all faiths
who are newly diagnosed with cancer, those who
are undergoing chemotherapy, radiation therapy

The Cancer Counseling Center will continue to offer
support groups as part of the comprehensive psychosocial
care available to patients and families. Research has

or bone marrow transplant. Skilled in working
with issues of spiritual diversity, chaplains are
important members of the cancer services team

demonstrated the effectiveness and importance of such

serving as spiritual companions who are often

groups especially as the groups reduce psychosocial

called upon to assist patients in communication

distress by decreasing isolation, help to normalize the

with local clergy or provide for sacramental needs.

emotions associated with a diagnosis of cancer, provide
answers to specific common problems, and enhance
feelings of hope and heightened self-esteem.
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Available 24 hours a day at all Metro Region

regional

I

activities

I

Tumor Boards
and

specialty

case

conferences

Multi-Disciplinary tumor boards and specialty case

dialog among multi-specialists. The outcome

conferences are offered weekly and/or monthly to educate

consists of recommendations that lead the way

health care providers, improve the quality of care for our

for “Best” practice patterns for treatment. It is

patients and to stimulate consultative discussion between

important to note that patient names are always

various specialties.

withheld to protect a patient’s confidentiality and
privacy. To present a case call 414-649-7290.

The consultative forums allow physicians to present
cases of special interest. An overview of the diagnostic

The serial conferences listed below are open to

findings is followed by a professional and consultative

all health care providers of Aurora Health Care.

Conference

Location

Room

Frequency

Day

Time

Tumor Board

SLMC

Health Science Classroom #3

Weekly

Friday

1 2:00 pm

Tumor Board

ASMC

Rapkin Auditorium

Weekly

Friday

12:00 pm

Tumor Board

WAM H

Conference Room A/B

Weekly

Friday

12:00 pm

Tumor Board

AMC in Hartford

Third Floor Conference Room

Monthly

Fourth Tuesday

12:00 pm

Tumor Board

AMC in Kenosha

TBA

Monthly

Second Friday

12:00 pm

Endocrine Case Conference

SLMC

Health Science Classroom #3

Weekly

Tuesday

12:00 pm

Radiosurgery/Neurosurgery
Conference

SLMC

DVI

Weekly

Tuesday

7:30 am

Breast Conference

5LMC

Health Science Classroom #3

Weekly

Wednesday

7:30 am

Breast Conference

ASMC

2nd Floor Surgical Conf. Rm

Every Other Week

Thursday

7:30 am

-

Reading Room

Aurora Medical Center in Hartford
1032 East Sumner Street
Hartford, WI 53027

Aurora Sinai Medical Center (ASMC)
945 North 12th Street
Milwaukee, WI 53233

Aurora Medical Center in Kenosha
10400 75th Street
Kenosha, WI 53142

St. Luke’s Medical Center (SLMC)
2900 West Oklahoma Avenue
Milwaukee, WI 53215

-

-

-

-

-

-

-

-

-

1:00 pm
1:00 pm
1:00 pm
1:00 pm
1:00 pm
1:00 pm

8:30 am

9:00 am
9:00 am

West Allis Memorial Hospital (WAMH)
8901 West Lincoln Avenue
West Allis, WI 53227

regional

activities
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2000 Primary Site Table
for metro region

cancer

AMC

ASMC

SLMC

WAMH

programs

N/A

A

A

N/A

A

N/A

A

N/A

570

38

1830

240

319

29

79

33

3138

0

0

2

0

0

0

0

2

0

Lip

1

0

9

1

1

0

0

Tongue

12

0

0

0

4

0

0

Floor of Mouth

9

0

0

7

1

1

0

0
0

0

4

0

Gum

0

0

2

0

0

0

0

2

0

Palate

0

3

0

1

0

0

5

0

0

0

0

0

5

0
0

0

4

0

Other Parts Mouth
Parotid Gland

0

0

3

0

2

0

0

6

1

Tonsil

0

0

2

0

1

0

0

Oropharynx
Nasopharynx
Pyriform Sinus

3

0

2

0

0

2

0

0

0

0

1

0

0

0
0

All Sites
Oral Cavity

0

1

0

0

0

0

0

0
0

0

0

0

0

1

0

5

0

0

0

0

0

Other

0
6

0

Digestive System
Esophagus

43

3

23

3

1

0

39

1

1

0

0
1

55

5
6

0

Stomach

8
7

8

1

Colon

274

2

3

0

Rectum
Anus/Anal Canal

0

0

Hypopharynx

3

162

19

70

53
17

26

1

35

8

3

0

0

3

6
0

0

0
0

3

0

20

2

4

0

0

29

0

Liver

10

0

43

4

1

4

Pancreas

71

4

7

0

21

1

0

0

31

0

Other

0

2

0

0

2

0
0

0

2
30

0

Nasal/Sinus
Larynx
Lung/Bronchus

20

3

0

1

0

62

5

249

28

55

5

3

422

15

1

0

4

0

3

0

0

8

0

Other

17

3

59

12

12

1

5

4

0

0

0

7

0

0

4
0

2

0

4

0

1

0

0

0

7

2

0

0

0

18

0

Respiratory System

Blood & Bone Marrow
113
Leukemia
11
Other
Bone
Connect/Soft Tissue
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12

5
2

2

0
4

2

SLMC

WAMH

AMC

ASMC

A

N/A

A

N/A

A

N/A

A

N/A

313$

570

38

1830

240

319

29

79

33

35
72

10
15

0

8
5

0

8

2

3
0

0

1

13
41

1

Other
Breast

637

125

10

344

37

93

2

20

6

Female Genital
Cervix Uteri
Corpus Uteri

69
111

25
21

0

0

1

10
7

0
0

0
1

Vulva

70
19

0
0
2

Other

8

0

Male Genital
Prostate

295

All Sites
Skin
Melanoma

Ovary

Testis
Other
Urinary System
Bladder
Kidney/Renal

16
1

138

31

2
11

10
9

0

67
38
8

11
2

8
1

1

3
0
0

0

4

4

0

0

0

60
1

5
0

188
13

27

8

5

1

0

1

0

0
0

0
0

0

1
0

4
0

75
54

11

2
2

2

0

4

34
15

Other

86
6

33
11
1

Brain & CNS
Brain

40

2

0

Other

17

2

0

Endocrine
Thyroid

49
7

13
0

0
0

28

Other

Lymphatic System

142

21

Unknown Primary

63

Other/Ill-Defined
Totals

14
1

0

0
0

2

0

0
0

7
3

4
1

0

1
0

0

0

1

2

1

0

0

0

0

0

0

0

1
0

4
0

1

7

0

1
0

1
0

0

74

18

18

2

5

4

13

1

39

3

6

1

0

0

14

3

0

11

0

0

0

0

0

3138

570

38

1830

240

319

29

79

33

This report excludes carcinoma in situ cases of the cervix and basal cell carcinomas of the skin.
A=Analytical, N/A=Non-Analytical

statistical

review
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2000 Data Review
by metro

region

facilities

3,138 new cancer cases were seen in the
Metro Region in 2000. The number of
2043
1-833-———-——-

—
—

ft-

87g37

1

i—I

•

SLMC

•

ASMC

new cancer cases has increased at all the
facilities from the previous year of 1999.
Site numbers include St. Luke’s Medical

AMC

Center 2,070 (includes SLSS) with 86%
classified as analytical (diagnosed and or

I

treated within the first course of treat
ment), Aurora Sinai Medical Center, 348

785

with 90% analytic, West Allis Memorial
Hospital 608 with 94% analytic and
Aurora Medical Center in Hartford with
1 12 cases of which 78% were analytic.

co

64

64

-I

-I

54

•

Males

I Females

More women than men were seen at all Metro Region sites in
2000. In total, 1,771 or 56% were women with 1,366 or 44%
being male. According to the estimated new cancer cases for
2002 based on the incidence rates from the NCI SEER program
the sex ration is even (50/50). State of Wisconsin’s Cancer
Incidence and Mortality Report for 1998, cancer rates were
higher for women for all primary site groups. The annual cancer
incidence rate was 423 per 100,000 population for males and
339 per 100,000 population for females. Of the total number
of cases the incidence was split 50/50.

Age at Diagnosis Within Metro

we
When comparing age differences among the Metro Region Hospitals
Center
Medical
Sinai
Aurora
at
diagnosed
being
patients
younger
find
with a mean age of 65. At St. Luke’s Medical Center and West Allis

35%
30%
25%

Memorial Hospital the mean age is 75 with St. Luke’s Medical Center
than
showing a larger portion of the patients being diagnosed younger
are being
patients
the
Hospital,
Memorial
Allis
West
at
whereas
mean,
the
of
diagnosed at ages slightly higher than the mean. Of the key findings
of the
60%
that
is
report
Mortality
and
Incidence
Cancer
Wisconsin
the
newly diagnosed cases in 1998 were age 65 and older.

20%
15%
10%
5%
0
0-29

page50

30-39

40-49

50-59

data

60-69

review

70-79

80-89

90+

When comparing the top five sites in
•

Breast

•

Lung

order of decreasing frequency in the
Metro Region to the incidence of cancer
cases reported by the state and the

16%
B

Colorectal

B

Prostate

D

Bladder

National Cancer Data Base (NCDB),
it is noted that the Metro Region sees
a higher percentage of breast cancer
cases (1 9%), fewer prostate cases (9%)
and a relatively equal number of lung
(14%), colorectal (12%) and bladder
cases (5%).

3%

3%

0%

1%

I

•

Other

D

Amlnd

Review of all (3,1 38) new cases in 2000 shows the
population served at St. Luke’s Medical Center and
West Allis Memorial Hospital is predominantly white

B

Asian

•

Black

central city location of Aurora Sinai Medical Center

•

White

serves a more diverse population with the majority

with 97% and 99% respectively. By contrast the

being of African American (49%) descent, with 1%
American Indian, 1% Asian and 1% Other.

!1T1T

r.ivi

TF7EI1fli1 EZrI

ii1TI.iiii ii iii!1

1*

240

B Analytical

The analytical percentages at each facility are as follows: St. Luke’s
Medical Center 88% classified as analytical (diagnosed and or treated

I I

within the first course of treatment), Aurora Sinai Medical Center 92%
analytical, West Allis Memorial Hospital 91% analytical and Aurora

II,

Medical Center in Hartford 71% analytical.

38
29

I,
I
U

33/79
I
AkA.

data

review
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L

•

a

•
•

•
a

•

•

Jeffrey Butler, MD Urology
Jacque Coons, RRT Quality Management
Chris Cullen, RN, MBA Quality Manager

•
•

•

C/L
•
a

•

•

•

Roger Pellman, MD Radiology
J. Pickeral, MD Pathology
Mitchell Pincus, MD Radiation Oncology

•

Becky Pogacar, RN, MSN Nursing
Kim Reed, RN Inpatient Nursing
Diane Reif, RN Patient Care Manager
Lisa Robinson, RHIA, CTR Clinical Data Registries

•

•

•
•
•

•

•

•

•
•

Ronald Grossman, MD Radiology
Uday Gupte, MD Gastroenterology
Barb Haag-Heitman, RN Women’s Health

•
•

•

•

a

•

Sheri Hackbarth, RHIA Cancer Registry
Robert Hall, MD Pathology
John P. Hanson, MD Medical Oncology
Ronald Hart, MD Medical Oncology

•

•
•

•

Pat Kadlec, RN Outpatient Nursing
Mary Kannenberg, RHIA Quality Management/CIS
John Kelly, MD Otolaryngology

•

•
•

Oza Holmes, RN, OCN Breast Health Center
Margery Howard, MD Medical Oncology
Rakesh Jagetia, MD Chairman, Radiation Oncology
Julie Jensen, RN, MSN, NP Nursing

C

•

•
•
•

•

•
•

Thomas Kinney, MD Plastic Surgery
Jeffrey Knajdl, MD Psychiatry

•

Daniel Kopesky, MD OB/GYN
William Laffey, MBA Regional Director Cancer Services

•
•

•

a

‘

C

•
•

•

•
L

•

•
•

members

a

a

•

I

•

I

•

Nileshkumar Patel, MD Pain Management
Wendy Paulson, SLSS Oncology
Jorge Pellegrini, MD Pathology

•

Mark Gennis, MD Internal Medicine
Vicki George, RN, PhD Administration
Perry Gould, MD Radiation Oncology

committee

•

•

Lawerence Dubin, MD Radiology
A. Craig Evans, MD Gynecologic Oncology
Donald Feinsilver, MD Psychiatry
Cindy Ganzel, RN, RHIT, CTR Cancer Registry
Daniel Geenen, MD Gastroenterology

cancer

David Munoz, MD Family Practice
Sharon Neidinger, RN VLCC
Michael Nordstrom, MD Otolaryngology
William Pao, MD Radiation Oncology

•
C

•

•

Tracy Miller, Cancer Registry
Mahmood Mirhoseini, MD Cardiothoracic Surgery
Sara Moldenhauer, RN, SGHJK

•

•

Jeffrey Derus, MD Chairman, Urology
Jan Dietrich, RN VNA
Ajit Divgi, MD Medical Oncology
William Donegan, MD Chairman, Surgery
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Angela Mengelt, MS Genetic Counselor
Donna Metoff, RN, MSN Inpatient Nursing
Wendy Mikkelson, MD Breast Surgery

•

•

Jerome Buboltz, MD Internal Medicine
Brian Butler, MD Urology

Janet Lotegeulaki, RN, OCN-CNS
Pamela Lyon, RN, OCN Breast Care Coordinator
Pamela Maier, RN Inpatient Nursing

Rev. Marcia Marino, Pastoral Care
Linda Martin, BSW Social Services
Jennifer Martone, RN, MSN Inpatient CNS
Mary Mavraganis, MS Social Services

•

•

Kenneth Bastin, MD Radiation Oncology
Diane Beier, CICSW Social Services
Nancy Briggs, RN, OCN Research
James Bruckman, MD Radiation Oncology

Margaret Lange, RN Outpatient Oncology
Ann Lefever, PhD Immunotherapy
Patricia Leithen, MD Family Practice
David Lewis, MD General Surgery

•

•

•

•

Patty Abella, RN, MSN Medical Oncology
Betty Amuzu, MD OB/GYN
Saleem Bahktiar, MD General Surgery
Linda Barrows, MD Physical Medicine & Rehab

Terence Roth, MD Surgery
Mary Runge, RN, MBA VNA Hospice Services
Lori Sadowski, RN Inpatient Nursing
Suzanne Schmidt, RN Breast Coordinator
Jane Seymour, RHIT, CTR Cancer Registrar

•

•

a

•

a

•

a

a

•

I

Gary Shapiro, MD Medical Oncology
Monique Swiecichowski, RN Research
Robert Taylor, MD Medical Oncology
Donna Theesfeld, RN Quality Management
Mary Tiller, MD Pain Management
Sue Toth, RN Breast Care Coordinator
Allen Torkelson, MD Medical Oncology
Jonathan Treisman, MD Medical Oncology

L

a

C
a
•

a

a
I

•

a

a

a

a

•

a

a

a

a

•

•

I

I

Walter Wong, MD Radiation Oncology
JoAnna Yeh, PharmD Pharmacy
Sol Yoder PharmD Oncology Pharmacy
George Yu, MD Pathology

I

•

Carol Tutino, RN, CCRC Research
Kerry Twite, RN, OCN-CNS VLCC
Shelly Underhill, MD Pathology
Vicki VoIp, RN, MSN Quality Management
Matt Wadell, RN, 8GHJK
Marija Weidman, RN, MSN Business & Market Dev.
Mark Wenzel, MD Radiology
Phil Whitton, RU Manager Radiation Oncology

a

•

a

Aurora Medical Center
1032 East Sumner Street

bAurnra Health Care
www.AuroraHeaithcare.org

Aurora Sinai Medical Center
945 North 12th Street
Milwaukee, WI 53233
St. Luke’s Medical Center
2900 West Oklahoma Avenue
Milwaukee, WI 53215

j
j

St. Luke’s South Shore*
5900 South Lake Drive
Cudahy, WI 53110
West Allis Memorial Hospital
8901 West Lincoln Avenue
West Allis, WI 53227
*inciuded in St. Luke’s Medical center Data

$

Aurora Health care
2900 West Oklahoma Avenue
Milwaukee, WI 53215
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